Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 100%Moderate 0 · 0%High 0 · 0%

Adverse events: all grades · non‐hospitalised individuals with COVID‐19

Bamlanivimab showed no clear difference in adverse events: all grades compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 0.99 [0.66, 1.5]
1 study · 257 participants
Low

Adverse events: all grades · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Bamlanivimab/etesevimab showed no clear difference in adverse events: all grades compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 1.15 [0.83, 1.59]
1 study · 1035 participants
Low